Lv3
210 积分 2023-09-18 加入
The Chemoimmunotherapy Revolution in Resectable NSCLC—The Times They Are A-Changin’
30天前
已完结
Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer
1个月前
已完结
Stereotactic Radiation Therapy in Early Non–Small Cell Lung Cancer and Interstitial Lung Disease
1个月前
已完结
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
1个月前
已完结
[Clinical update in critical care of pulmonary medicine 2023]
1个月前
已完结
Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI
1个月前
已完结
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study
1个月前
已完结
Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis
2个月前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
2个月前
已完结
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study
2个月前
已完结
皖公网安备34019202002308
